Purple Biotech Schedules Shareholder Meeting for December 15
Ticker: PPBT · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1614744
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance
TL;DR
Purple Biotech calling shareholder meeting Dec 15 - important votes coming up.
AI Summary
Purple Biotech Ltd. announced on October 28, 2025, that an Extraordinary General Meeting of Shareholders will take place on December 15, 2025, at 4:30 p.m. Israel time. The meeting will be held at the Company's facilities in Rehovot, Israel. Shareholders will vote on important company matters.
Why It Matters
This meeting is crucial for shareholders to have a say in significant corporate decisions that could impact the company's future direction and value.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a shareholder meeting, not indicating any immediate financial or operational risks.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- October 28, 2025 (date) — Announcement date
- December 15, 2025 (date) — Shareholder meeting date
- 4:30 p.m. Israel time (time) — Shareholder meeting time
- Rehovot, Israel (location) — Company address
FAQ
When will the Extraordinary General Meeting of Shareholders be held?
The meeting will be held on Monday, December 15, 2025.
What time is the shareholder meeting scheduled for?
The meeting is scheduled for 4:30 p.m. Israel time.
What is the name of the company filing this report?
The company filing this report is Purple Biotech Ltd.
Where is the company's principal executive office located?
The company's principal executive office is located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
What type of report is Purple Biotech Ltd. filing?
Purple Biotech Ltd. is filing a Form 6-K, Report of Foreign Private Issuer.
Filing Stats: 658 words · 3 min read · ~2 pages · Grade level 18.8 · Accepted 2025-10-28 16:08:18
Filing Documents
- ea0262767-6k_purple.htm (6-K) — 21KB
- ea026276701ex99-1_purple.htm (EX-99.1) — 89KB
- ea026276701ex99-2_purple.htm (EX-99.2) — 5KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- ex99-1_002.jpg (GRAPHIC) — 5KB
- ex99-1_003.jpg (GRAPHIC) — 5KB
- ex99-2_001.jpg (GRAPHIC) — 189KB
- ex99-2_002.jpg (GRAPHIC) — 126KB
- 0001213900-25-103079.txt ( ) — 569KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. October 28, 2025 PURPLE BIOTECH LTD. By: /s/ Gil Efron Gil Efron Chief Executive Officer 2